Beimei Pharmaceutical Company is a Chinese pharmaceutical company headquartered in Shanghai. In 2016, it ranked first on the Fortune China 500 list of the country’s largest publicly traded companies. Beimei has a diverse product lineup that includes generic and original drugs, vaccines, biopharmaceuticals and medical devices.
Brief History of Beimei Pharmaceutical
The company’s original business was producing and marketing generic medicines. In 1992, Beimei Pharmaceutical became the first Chinese pharmaceutical company to produce a branded product, which was a combination drug for hypertension and atherosclerosis. In 1998, the company became a wholly owned subsidiary of Beijing Jinmei Pharma Group Corporation.
Products and Services
Beimei Pharmaceutical Company is a Chinese drug manufacturer that produces generic and brand-name medications. The company has a wide range of products, including drugs for cardiovascular diseases, gastroenterology, respiratory diseases, and pain relief.
Board of Directors
Basic Things About Beimei Pharmaceutical Company
1. Who is on the Board of Directors?
The Beimei Pharmaceutical Company has a Board of Directors that consists of five individuals.
2. How long have they been on the Board?
The five individuals have all been on the Board for a total of nine years.
3. What do they do on the Board?
Each Board Member has specific responsibilities and duties within the company.
4. What are some of the major accomplishments of the Board?
Some notable achievements of the Beimei Pharmaceutical Company’s Board of Directors include helping to increase revenues by over 100% and doubling market share within their respective industries.
Beimei Pharmaceutical Company has posted their latest financial report on their website. The report covers the company’s activities from December 2014 to November 2015.
Income and Expenses:
The company’s total assets increased by 18% to RMB 14,589,000 (USD 2,812,000) at the end of November 2015 from RMB 12,287,000 (USD 2,596,000) at the end of December 2014. Net liabilities decreased by 3% to RMB 13,906,000 (USD 2,890,000) at the end of November 2015 from RMB 14,128,000 (USD 2,910 000) at the end of December 2014.
Beimei Pharmaceutical Co. The product, called ST-246, is an intravenous TB treatment that uses a new drug combination therapy approach. The therapy consists of rifampicin and isosorbide dinitrate administered together over a period of two weeks. With the rapidly growing global problem of TB, BPCO’s new product candidate may provide an important new option for patients suffering from this disease.
Beimei Pharmaceutical Company is an innovative pharmaceutical company focused on developing new and innovative treatments for patients around the world. We strive to provide top-quality services and products that will benefit our customers and help them live healthier lives. Thanks for reading!